Endothelial function and oxidative stress

被引:130
作者
Ogita, H
Liao, JK
机构
[1] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Boston, MA USA
来源
ENDOTHELIUM-JOURNAL OF ENDOTHELIAL CELL RESEARCH | 2004年 / 11卷 / 02期
关键词
antioxidant therapy; atherosclerosis; cardiovascular disease; reactive oxygen species;
D O I
10.1080/10623320490482664
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Increased oxidative stress impairs endothelial function and is thought to mediate vascular disease. Several pathological conditions increase the production of reactive oxygen species (ROS) in the vascular wall, including hypercholesterolemia, diabetes, and hypertension. These conditions are associated with endothelial dysfunction and cardiovascular disease. Thus, overall vascular function is dependent upon the balance of oxidant and antioxidant mechanisms, which determines endothelial function. Endothelial function is usually defined as nitric oxide (NO) production and/or bioavailability. Because ROS can interact and inactivate NO, vascular oxidative stress can lead to decrease NO bioavailability. This results in endothelial dysfunction and increased risk of cardiovascular diseases. Several pharmacological approaches have been used to improve endothelial function and decrease oxidative stress. These include treatment modalities that augment the antioxidant defense mechanisms, increase NO production, and inhibit ROS-generating enzymes. This review provides an overview of the relationship between endothelial function and oxidative stress.
引用
收藏
页码:123 / 132
页数:10
相关论文
共 145 条
[1]   REDOX REGULATION OF FOS AND JUN DNA-BINDING ACTIVITY INVITRO [J].
ABATE, C ;
PATEL, L ;
RAUSCHER, FJ ;
CURRAN, T .
SCIENCE, 1990, 249 (4973) :1157-1161
[2]   THE EFFECT OF CHOLESTEROL-LOWERING AND ANTIOXIDANT THERAPY ON ENDOTHELIUM-DEPENDENT CORONARY VASOMOTION [J].
ANDERSON, TJ ;
MEREDITH, IT ;
YEUNG, AC ;
FREI, B ;
SELWYN, AP ;
GANZ, P .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (08) :488-493
[3]   Assessment and treatment of endothelial dysfunction in humans [J].
Anderson, TJ .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1999, 34 (03) :631-638
[4]   IMMUNOSUPPRESSION BY GLUCOCORTICOIDS - INHIBITION OF NF-KAPPA-B ACTIVITY THROUGH INDUCTION OF I-KAPPA-B SYNTHESIS [J].
AUPHAN, N ;
DIDONATO, JA ;
ROSETTE, C ;
HELMBERG, A ;
KARIN, M .
SCIENCE, 1995, 270 (5234) :286-290
[5]   ATHEROSCLEROSIS - BASIC MECHANISMS - OXIDATION, INFLAMMATION, AND GENETICS [J].
BERLINER, JA ;
NAVAB, M ;
FOGELMAN, AM ;
FRANK, JS ;
DEMER, LL ;
EDWARDS, PA ;
WATSON, AD ;
LUSIS, AJ .
CIRCULATION, 1995, 91 (09) :2488-2496
[6]  
BEVILACQUA MP, 1993, ANNU REV IMMUNOL, V11, P767, DOI 10.1146/annurev.iy.11.040193.004003
[7]   Asymmetric dimethylarginine (ADMA):: A novel risk factor for endothelial dysfunction -: Its role in hypercholesterolemia [J].
Böger, RH ;
Bode-Böger, SM ;
Szuba, A ;
Tsao, PS ;
Chan, JR ;
Tangphao, O ;
Blaschke, TF ;
Cooke, JP .
CIRCULATION, 1998, 98 (18) :1842-1847
[8]   The nuclear factor kappa-B signaling pathway participates in dysregulation of vascular smooth muscle cells in vitro and in human atherosclerosis [J].
Bourcier, T ;
Sukhova, G ;
Libby, P .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (25) :15817-15824
[9]   CLONED AND EXPRESSED NITRIC-OXIDE SYNTHASE STRUCTURALLY RESEMBLES CYTOCHROME-P-450 REDUCTASE [J].
BREDT, DS ;
HWANG, PM ;
GLATT, CE ;
LOWENSTEIN, C ;
REED, RR ;
SNYDER, SH .
NATURE, 1991, 351 (6329) :714-718
[10]   Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension [J].
Butler, R ;
Morris, AD ;
Belch, JJF ;
Hill, A ;
Struthers, AD .
HYPERTENSION, 2000, 35 (03) :746-751